Delving into the Latest Updates on BioPharm Solutions, Inc. with Synapse

A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients

A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients.

开始日期2020-04-15

申办/合作机构

BioPharm Solutions, Inc.

100 项与 BioPharm Solutions, Inc. 相关的临床结果

登录后查看更多信息

0 项与 BioPharm Solutions, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 BioPharm Solutions, Inc. 相关的文献（医药）

Pharmaceutics3区 · 医学

Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide

3区 · 医学

ArticleOA

作者: Jin, Tuo ; Ge, Yuxuan ; Wu, Fei ; Hu, Zhenhua ; Qin, Yujie ; Chen, Jili

GLP-1 receptor agonists are a class of diabetes medicines offering self-regulating glycemic efficacy and may best be administrated in long-acting forms. Among GLP-1 receptor agonists, exenatide is the one requiring the least dose so that controlled-release poly(d,l-lactic-co-glycolic acid) (PLGA) microspheres may best achieve this purpose. Based on this consideration, the present study extended the injection interval of exenatide microspheres from one week of the current dosage form to four weeks by simply blending Mg(OH)2 powder within the matrix of PLGA microspheres. Mg(OH)2 served as the diffusion channel creator in the earlier stage of the controlled-release period and the decelerator of the self-catalyzed degradation of PLGA (by the formed lactic and glycolic acids) in the later stage due to its pH-responsive solubility. As a result, exenatide gradually diffused from the microspheres through Mg(OH)2-created diffusion channels before degradation of the PLGA matrix, followed by a mild release due to Mg(OH)2-buffered degradation of the polymer skeleton. In addition, an extruding–settling process comprising squeezing the PLGA solution through a porous glass membrane and sedimentation-aided solidification of the PLGA droplets was used to prepare the microspheres to ensure narrow size distribution and 95% encapsulation efficiency in an aqueous continuous phase. A pharmacokinetic study using rhesus monkey model confirmed the above formulation design by showing a steady blood concentration profile of exenatide with reduced CMAX and dosage form index. Mg(OH)2.

100 项与 BioPharm Solutions, Inc. 相关的药物交易

登录后查看更多信息

100 项与 BioPharm Solutions, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月28日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

JBPOS-0101 ( mGluRs )	婴儿痉挛更多	终止
Insulin controlled-release microneedle patch (Biopharm Solutions Inc) ( INSR )	糖尿病更多	无进展
Natural interferon alpha(BioPharm Solutions, Inc.) ( IFNAR )	-	无进展